Journal News

How an oral antiviral drug confuses the replication machinery of SARS-CoV-2

Gillian Rutherford
By Gillian Rutherford
Aug. 26, 2021

A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus. The findings were published recently in the Journal of Biological Chemistry.

Matthias Götte
This mutagenesis model of molnupiravir shows SARS-CoV-2 polymerase
(oval)–mediated nucleotide incorporation into the RNA primer
(grey circles)/template (white circles). Plus and minus signs indicate
RNA sense. A, C, G and U refer to natural nucleotide bases, and M
refers to the active forms of molnupiravir. Three small circles indicate
the triphosphate form of nucleotides. (1) Molnupiravir competes with CTP
for incorporation during synthesis of the negative RNA strand
(copy of the genome). (2) When embedded in the template, molnupiravir
base-pairs with either ATP or GTP. (3) Incorporation of ATP results
in mutagenesis. (4) The mutation is fixed as RNA synthesis continues.
The boxed information provides a summary of events that lead to drug-induced
G to A and C to U transition mutations.

The researchers demonstrated the underlying mechanism of action by which the antiviral drug molnupiravir changes the viral genome, a process known as excessive mutagenesis or error catastrophe.

Matthias Götte is a professor and chair of the medical microbiology and immunology department in the university’s Faculty of Medicine & Dentistry and a member of the Li Ka Shing Institute of Virology. “The polymerase, or replication engine of the virus, mistakes molnupiravir molecules for the natural building blocks required for viral genome replication and mixes them in,” Gotte said. “It causes the polymerase to make sloppy copies — nonsense genomes that are useless and not viable.”

 In clinical trials for efficacy, molnupiravir eliminated SARS-CoV-2 infectivity in newly diagnosed patients after five days of treatment. The drug is taken as a pill, making it much easier to administer than other approved treatments such as remdesivir or monoclonal antibodies, which must be given intravenously.”

“Our work to demonstrate that the effect of the drug is indeed mediated by the viral polymerase is reassuring, because if the drug somehow generates mistakes in the virus and you don’t know how it happens, there could be other mechanisms at work that could also harm the cell. Still, the safety of the drug for COVID-19 patients remains to be evaluated and monitored.”

The ongoing hunt for a weapon against pandemics

The active form of molnupiravir first was identified as a broad-spectrum antiviral at Emory University in Atlanta, Georgia. In 2003, it was developed as a treatment for chronic hepatitis C, but it was dropped due to possible side effects associated with long-term use. The drug then was developed as an influenza antiviral, because the course of treatment for flu is much shorter. The focus of testing switched to SARS-CoV-2 after the COVID-19 pandemic emerged. The drug now is being developed in partnership by Merck and Ridgeback Biotherapeutics.

Merck has made deals with five generic drugmakers in India to make molnupiravir, and at least one of them has applied for approval to use it on an emergency basis, as at least 350,000 new infections are diagnosed in that country every day and vaccination levels are low.

Götte and his team previously uncovered the mechanisms of action for remdesivir, a now-approved treatment that inhibits replication of the SARS-CoV-2 virus, and baloxavir, an influenza drug. 

Next, they will test molnupiravir’s mechanism of action against the polymerases of some of the other viruses the World Health Organization has identified as having high epidemic potential.

“All are recognized as emerging pathogens where we need to develop countermeasures,” Götte said. “We need to be prepared with broad-spectrum antivirals that can serve as a first line of defense.

“Even once vaccines are developed, we can’t get them into all the arms at once,” he said. “To really fight outbreaks and epidemics, one tool is unlikely to be sufficient.”

Gillian Rutherford
Gillian Rutherford

Gillian Rutherford is a communications advisor for the University of Alberta.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Finding the right research path

Finding the right research path

Sept. 16, 2021

Karen Bornfeldt, an associate editor for the Journal of Lipid Research, investigates how diabetes increases cardiovascular disease risk.

From the journals: JBC
Journal News

From the journals: JBC

Sept. 15, 2021

Antibody interactions that change cytotoxicity. An atlas for macrophage activation. Anti–Zika virus natural products. Read about papers on these and other topics.

Noboru Sueoka (1929 – 2021)

Noboru Sueoka (1929 – 2021)

Sept. 13, 2021

Sueoka made widely known contributions to our understanding of DNA replication. Indeed, he coined the term “origin of replication.”

From CRISPR to glowing proteins to optogenetics

From CRISPR to glowing proteins to optogenetics

Sept. 12, 2021

Three pioneering technologies have forever altered how researchers do their work and promise to revolutionize medicine, from correcting genetic disorders to treating degenerative brain diseases.

Lobsters hold the secret of a long, cancer-free life in their genes

Lobsters hold the secret of a long, cancer-free life in their genes

Sept. 11, 2021

More than a mere delicacy, the humble lobster could teach us a lot about healthy aging.

Personal chemistry: Proteomics tackles privacy concerns

Personal chemistry: Proteomics tackles privacy concerns

Sept. 9, 2021

Sharing raw data is an important norm for the proteomics community. But as clinical studies become more detailed, researchers may need to clamp down to protect patient privacy.